Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Rating) was the target of a significant drop in short interest in April. As of April 30th, there was short interest totalling 56,900 shares, a drop of 20.2% from the April 15th total of 71,300 shares. Approximately 0.5% of the company’s stock are sold short. Based on an average daily volume of 23,100 shares, the short-interest ratio is currently 2.5 days.
A number of equities analysts have weighed in on ATXS shares. Zacks Investment Research downgraded shares of Astria Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. HC Wainwright reiterated a “buy” rating and set a $13.00 price target on shares of Astria Therapeutics in a report on Friday, March 11th.
NASDAQ:ATXS opened at $4.02 on Tuesday. The company’s 50 day moving average price is $6.27 and its 200-day moving average price is $6.06. Astria Therapeutics has a 52 week low of $3.83 and a 52 week high of $15.72. The stock has a market cap of $52.33 million, a price-to-earnings ratio of -0.52 and a beta of 1.38.
A number of hedge funds have recently modified their holdings of the stock. Perceptive Advisors LLC purchased a new stake in Astria Therapeutics in the third quarter worth approximately $17,323,000. RA Capital Management L.P. purchased a new stake in Astria Therapeutics in the third quarter worth approximately $11,158,000. VR Adviser LLC purchased a new stake in Astria Therapeutics in the third quarter worth approximately $4,765,000. Citadel Advisors LLC purchased a new stake in Astria Therapeutics in the third quarter worth approximately $2,746,000. Finally, Commodore Capital LP purchased a new stake in Astria Therapeutics in the third quarter worth approximately $2,115,000. Institutional investors own 51.79% of the company’s stock.
Astria Therapeutics Company Profile (Get Rating)
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema.
- Get a free copy of the StockNews.com research report on Astria Therapeutics (ATXS)
- Option Care Health Stock is Making a Healthy Pullback
- MarketBeat Podcast: Trading Volatile Markets While Preserving Capital
- Warby Parker Stock Is A High-Probability Candidate For A Short-Squeeze
- Concentrix: High Debt and Struggling Margins
- Recession Fears Mount After Weak Manufacturing Data
Receive News & Ratings for Astria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.